605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
0 activities
A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
1 activities
A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
1 activities
APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies
1 activities
Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies
Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients
1 activities
Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients
LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies
1 activities
LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies
Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
1 activities
Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
Synergistic Antitumor Effect of a Novel First-in-Class Small Molecule OPB-111077 That Inhibits Mitochondrial Oxidative Phosphorylation in Combination with Alkylating Agent
1 activities
Synergistic Antitumor Effect of a Novel First-in-Class Small Molecule OPB-111077 That Inhibits Mitochondrial Oxidative Phosphorylation in Combination with Alkylating Agent
Targeted Therapy with CX4945 Biomimetic Nanodrug Delivery System for High-Risk B-Cell Acute Lymphoblastic Leukemia
1 activities
Targeted Therapy with CX4945 Biomimetic Nanodrug Delivery System for High-Risk B-Cell Acute Lymphoblastic Leukemia
Targeting Nucleotides Dependency Via SIRT3 Inhibition to Overcome Metabolic Plasticity and Flexibility of Dlbcls
1 activities
Targeting Nucleotides Dependency Via SIRT3 Inhibition to Overcome Metabolic Plasticity and Flexibility of Dlbcls
The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function
1 activities
The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function
Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
1 activities
Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma